GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Summary

An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease

Timeline

Start

2023-01-05

Primary completion

2025-02-13

Completion

2025-02-13

Outcome

Outcome not reported

Stopped: “Study terminated as data obtained from this non-placebo-controlled trial may not be informative for the interpretation of the benefits and risks of osivelotor”

Drugs

Indications